IE 11 is not supported. For an optimal experience visit our site on another browser.

Immudyne Completing Audited Financials

/ Source: GlobeNewswire

FLORENCE, Ky., March 14, 2011 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD), the leading supplier of Yeast Beta Glucan, announced today that the Company expects to be fully reporting by the first week of April, 2011, at which time two years of audited financials will be uploaded to . As previously disclosed, New York based PKF LLP has been retained to conduct the audit.

Immudyne recognizes the importance of providing shareowners transparency on an ongoing basis.

About PKF LLP

PKF LLP Certified Public Accountants has a 90-year old tradition of excellence and quality client service. Since 1969, PKF has been a member of PKF International Ltd., a network of independent accounting, auditing, tax and business advisory firms with members located in over 250 cities worldwide.  It also is a member of PKF North America with members in over 80 cities in the United States. 
  

About Immudyne

Immudyne manufactures, distributes and sells all-natural yeast beta glucan products for immune system support.

Immudyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com (currently being transformed.) Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates,""believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

CONTACT: Immudyne, Inc. Mark McLaughlin +1-914-714-8901 MarkMcL@immudyne.com